Skip to main content
    I

    IDEXX Laboratories Inc (IDXX)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $700.65
    -3.58 (-0.51%)

    Market Cap: $55.48B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    IDEXX Laboratories Inc (IDXX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 2, 2026. Financial statements from company filings, amounts in US dollars.

    IDEXX Laboratories reported revenue of $4.30B for the fiscal year ended Dec 31, 2025, up 10.4% from the year before. That year, net income was $1.06B with a net margin of 24.6%, operating cash flow was $1.18B and free cash flow was $1.06B. The quarter ended Sep 30, 2026 had revenue of $1.21B and net income of $317.14M.

    Revenue and Margins

    The operating margin was 31.6% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $1.78B, a compound annual rate of 10.3%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$4.30B+10.4%61.8%31.6%24.6%
    Dec 2024$3.90B+6.5%61.0%29.0%22.8%
    Dec 2023$3.66B+8.7%59.8%30.0%23.1%
    Dec 2022$3.37B+4.7%59.5%26.7%20.2%
    Dec 2021$3.22B+18.8%58.8%29.0%23.2%
    Dec 2020$2.71B+12.5%58.0%25.7%21.5%
    Dec 2019$2.41B+8.8%56.7%23.0%17.8%
    Dec 2018$2.21B+12.4%56.1%22.2%17.0%
    Dec 2017$1.97B+10.9%55.7%21.0%13.4%
    Dec 2016$1.78BN/A54.9%19.7%12.5%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 19.4% from the year before. In the quarter ended Sep 2026, net income rose 15.5% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$4.30B$3.90B$3.66B$3.37B$3.22B$2.71B$2.41B$2.21B$1.97B$1.78B
    Cost of revenue$1.64B$1.52B$1.47B$1.36B$1.33B$1.14B$1.04B$971.70M$871.68M$799.99M
    Gross profit$2.66B$2.38B$2.19B$2.00B$1.89B$1.57B$1.37B$1.24B$1.10B$975.44M
    Research and development$251.21M$219.79M$190.95M$254.82M$161.01M$141.25M$133.19M$117.86M$109.18M$101.12M
    Operating income$1.36B$1.13B$1.10B$898.76M$932.03M$694.52M$552.85M$491.33M$413.03M$350.24M
    Net income$1.06B$887.87M$845.04M$679.09M$744.84M$582.13M$427.79M$377.05M$263.27M$222.05M
    EBITDA$1.51B$1.26B$1.21B$1.01B$1.04B$790.52M$640.86M$574.51M$496.17M$429.30M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$1.21B$1.22B$1.14B$1.09B$1.11B$1.11B$998.43M$954.29M$975.54M$1.00B$964.10M$901.60M
    Gross profit$764.30M$779.09M$722.74M$658.11M$683.35M$694.73M$623.38M$570.66M$596.04M$619.16M$593.07M$526.17M
    Operating income$402.35M$425.57M$362.59M$315.61M$354.85M$373.05M$316.53M$261.69M$303.89M$263.80M$298.96M$245.30M
    Net income$317.14M$338.41M$278.45M$248.19M$274.61M$293.99M$242.68M$216.15M$232.84M$203.30M$235.58M$194.52M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $847.84M exceeded cash and equivalents by $667.77M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$3.35B$3.29B$3.26B$2.75B$2.44B$2.29B$1.83B$1.54B$1.71B$1.53B
    Current assets$1.41B$1.40B$1.50B$1.10B$955.65M$1.06B$679.64M$654.17M$971.99M$845.58M
    Cash and equivalents$180.07M$288.27M$453.93M$112.55M$144.45M$383.93M$90.33M$123.79M$187.68M$154.90M
    Total liabilities$1.75B$1.70B$1.78B$2.14B$1.75B$1.66B$1.65B$1.55B$1.77B$1.64B
    Short-term debt$473.00M$417.79M$325.00M$653.98M$148.50M$49.99M$288.76M$398.94M$655.00M$611.00M
    Long-term debt$374.84M$449.79M$622.88M$694.39M$775.21M$858.49M$698.91M$601.35M$606.08M$593.11M
    Shareholder equity$1.61B$1.60B$1.48B$608.74M$689.99M$632.09M$177.47M-$9.51M-$54.11M-$108.35M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$3.71B$3.44B$3.39B$3.35B$3.39B$3.33B$3.21B$3.29B$3.35B$3.41B$3.35B$3.26B
    Total liabilities$1.84B$1.83B$1.83B$1.75B$1.83B$1.87B$1.77B$1.70B$1.73B$1.83B$1.78B$1.78B
    Cash and equivalents$197.54M$196.93M$200.53M$180.07M$208.17M$164.59M$163.97M$288.27M$308.64M$401.59M$397.43M$453.93M
    Shareholder equity$1.87B$1.61B$1.56B$1.61B$1.56B$1.46B$1.45B$1.60B$1.62B$1.58B$1.57B$1.48B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 89.8% of operating cash flow. Share repurchases came to 115.1% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$1.18B$929.00M$906.51M$542.98M$755.55M$648.06M$459.16M$400.08M$373.28M$353.64M
    Capital expenditures$124.68M$120.92M$133.63M$148.84M$119.55M$106.96M$154.97M$115.75M$74.38M$64.79M
    Free cash flow$1.06B$808.08M$772.88M$394.15M$636.00M$541.11M$304.19M$284.33M$298.89M$288.86M
    Dividends paidN/AN/AN/AN/A$990.00K$0$0N/A$0$4.73M
    Share repurchases$1.22B$837.03M$71.92M$819.71M$746.78M$182.81M$301.66M$369.32M$282.56M$304.09M
    Investing cash flow-$136.24M-$207.06M-$125.25M-$195.35M-$292.97M-$109.38M-$205.53M$138.60M-$138.69M-$90.79M
    Financing cash flow-$1.16B-$878.07M-$442.00M-$370.94M-$697.41M-$248.42M-$286.41M-$597.80M-$208.02M-$236.90M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$449.72M$347.16M$266.25M$355.76M$402.34M$185.74M$237.96M$262.02M$220.08M$248.31M$198.59M$249.85M
    Capital expenditures$28.93M$24.65M$31.98M$29.43M$31.11M$34.10M$30.03M$29.25M$28.09M$33.30M$30.27M$32.56M
    Free cash flow$420.79M$322.52M$234.26M$326.33M$371.23M$151.64M$207.94M$232.77M$191.99M$215.01M$168.31M$217.29M
    Last 12 quarters

    Frequently Asked Questions About IDXX

    What is IDEXX Laboratories' annual revenue?

    IDEXX Laboratories reported revenue of $4.30B for the fiscal year ended Dec 31, 2025.

    How fast is IDEXX Laboratories' revenue growing?

    Revenue was up 10.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 8.5%.

    Is IDEXX Laboratories profitable?

    Yes. IDEXX Laboratories reported net income of $1.06B for the fiscal year ended Dec 31, 2025, with a net margin of 24.6%.

    How much free cash flow does IDXX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $1.18B minus capital expenditures of $124.68M produced free cash flow of $1.06B.

    How much debt does IDEXX Laboratories have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $374.84M, short-term debt of $473.00M and cash and equivalents of $180.07M.